A recent analysis of US pharmacy claims has revealed that only one in four patients prescribed Novo Nordisk’s Wegovy or Ozempic for weight loss continued using the medications two years later. The study, which provides a comprehensive view of real-world patient experiences, showed a steady decline in usage over time. The analysis, conducted by Prime Therapeutics and Magellan Rx Management,…